Association Between Serious Hypoglycemia and Calcium-Channel Blockers Used Concomitantly With Insulin Secretagogues.

Young Hee Nam, Colleen M Brensinger, Warren B Bilker, James H Flory, Charles E Leonard, Sean Hennessy

Journal: JAMA network open 2022;4(9):e2124443

PMID: 34473261

Free Full Text on PubMed Central View on PubMed

Abstract

This cohort study investigates whether serious hypoglycemia is reduced in a Medicaid population receiving calcium-channel blockers with insulin secretagogues.

Address: Therapeutics Research and Infectious Disease Epidemiology (TIDE), Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts.; Center for Pharmacoepidemiology Research and Training, Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia.; Endocrinology Service, Department of Subspecialty Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

DOI: 10.1001/jamanetworkopen.2021.24443

Link outs

Free resources

Full Text Sources:

Medical:

https://medlineplus.gov/diabetestype2.html

Subscription / membership required

Full Text Sources:

http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=linko...

MeSH Terms: Aged, Calcium Channel Blockers, Diabetes Mellitus, Type 2, Drug Interactions, Female, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Regular, Human, Insurance Claim Review, Male, Middle Aged, Secretagogues, United States